Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Myeloma: diagnosis complications and supportive care.

Morgan G.

Hematology. 2012 Apr;17 Suppl 1:S109-11. doi: 10.1179/102453312X13336169156177.

PMID:
22507795
2.

[Supportive care in multiple myeloma for continuing anti-myeloma therapies].

Shibayama H.

Rinsho Ketsueki. 2014 Oct;55(10):1999-2004. Review. Japanese. No abstract available.

PMID:
25297765
3.

Myeloma: making sense of a complex blood cancer.

Kelly MB, Meenaghan T, Dowling M.

Br J Nurs. 2010 Dec 9-2011 Jan 13;19(22):1415-21.

PMID:
21139523
4.

Successful bone reconstruction after bortezomib therapy in a myeloma patient.

Tanaka T, Yamasaki R, Omura H, Hino N.

Int J Hematol. 2011 Sep;94(3):221. doi: 10.1007/s12185-011-0913-9. Epub 2011 Aug 23. No abstract available.

PMID:
21861100
5.

Orthopaedics: Structural support.

Berglund J.

Nature. 2011 Dec 14;480(7377):S56-7. doi: 10.1038/480S56a. No abstract available.

PMID:
22169807
6.

[Multiple myeloma].

Abe M.

Nihon Rinsho. 2009 May;67(5):991-5. Review. Japanese.

PMID:
19432122
7.
8.

Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?

San Miguel JF.

Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982. No abstract available.

9.

Multiple myeloma.

Laubach J, Richardson P, Anderson K.

Annu Rev Med. 2011;62:249-64. doi: 10.1146/annurev-med-070209-175325. Review.

PMID:
21090965
10.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

11.

[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].

Cao ZG, Liu M, Zhou HW.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jan;34(1):74-5. Chinese. No abstract available.

PMID:
23597473
12.

Bisphosphonate therapy in the treatment of multiple myeloma.

Lawson MA, Ashcroft J, Croucher PI.

Curr Pharm Des. 2010;16(27):3028-36. Review.

PMID:
20722619
13.

Bortezomib induced a phrenic palsy in a multiple myeloma patient.

Nizeica V, Collet P, Marotte H.

Ann Hematol. 2013 Aug;92(8):1135-6. doi: 10.1007/s00277-013-1687-3. Epub 2013 Feb 1. No abstract available.

PMID:
23370597
14.

New developments with bortezomib in treating multiple myeloma.

Reddy GK.

Clin Lymphoma. 2004 Mar;4(4):215-6. No abstract available.

PMID:
15072611
15.

Supportive therapy in multiple myeloma.

Ludwig H, Zojer N.

Recent Results Cancer Res. 2011;183:307-33. doi: 10.1007/978-3-540-85772-3_15. Review.

PMID:
21509692
16.

[Update in multiple myeloma: international criteria for treatment response and renal complications].

Decaux O, Karras A.

Rev Med Interne. 2009 Dec;30(12):1080-3. doi: 10.1016/j.revmed.2009.09.003. Epub 2009 Oct 14. French. No abstract available.

PMID:
19833418
17.

Current treatments for renal failure due to multiple myeloma.

Kastritis E, Terpos E, Dimopoulos MA.

Expert Opin Pharmacother. 2013 Aug;14(11):1477-95. doi: 10.1517/14656566.2013.803068. Epub 2013 May 25. Review.

PMID:
23705905
18.

[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].

Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, Ueda Y, Fujisaki T.

Gan To Kagaku Ryoho. 2011 Feb;38(2):237-41. Japanese.

PMID:
21368487
19.

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E.

Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.

PMID:
19717380
20.

Effects of bortezomib on bone disease in multiple myeloma.

Drake MT, Rajkumar SV.

Am J Hematol. 2009 Jan;84(1):1-2. doi: 10.1002/ajh.21324. No abstract available.

Supplemental Content

Support Center